ArticleExperimental and therapeutic medicine2026
A nomogram for predicting recurrence-free survival in patients with high-risk GIST receiving adjuvant imatinib: A nationwide registry study.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predicting the prognosis of small intestinal stromal tumors in the post-imatinib era: a study based on the SEER database.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite adjuvant imatinib therapy, a substantial proportion of patients with high-risk gastrointestinal stromal tumor (GIST) experience disease recurrence. This study aimed to identify prognostic factors associated with poor recurrence-free survival (RFS) and develop a predictive nomogram for personalized clinical decision-making. In the present study, a retrospective analysis was conducted of 269 patients with modified Armed Forces Institute of Pathology-classified high-risk GIST who underwent macroscopically complete resection and received adjuvant imatinib therapy at 11 Taiwanese centers between 2013 and 2023. All patients were intended to receive 3 years of adjuvant imatinib and were categorized into disease-free (n=204) and recurrence (n=65) cohorts. Independent predictors of poor RFS were identified through multivariate Cox regression analysis and incorporated into a nomogram. Model performance was assessed using concordance index (C-index) and calibration plots. The cohort comprised 149 males and 120 females with a median age of 60.9 years (range, 29-88 years). At a median follow-up of 62.6 months, the 1-, 3- and 5-year disease-free survival rates were 97.0, 91.7 and 76.4%, respectively. Multivariate analysis identified male sex [hazard ratio (HR): 1.76, P=0.039], non-gastric tumor origin with duodenum showing highest risk (HR: 6.15, P<0.0001) and shorter imatinib duration with <1 year treatment showing HR: 3.91 (P=0.002) as independent predictors of poor RFS. The resulting nomogram demonstrated robust predictive performance with good calibration and C-index of 0.72. Nomogram-based prognostic stratification identified three distinct groups with 5-year survival rates of 99.2% (favorable prognosis), 68.1% (moderate prognosis) and 16.7% (poor prognosis). In the present study, a clinically applicable nomogram was developed that accurately predicts poor RFS in patients with high-risk GIST following surgery and adjuvant imatinib therapy. While external validation is needed before clinical implementation, this prognostic tool may facilitate individualized treatment strategies and patient counseling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.